Skip to main content

Advertisement

SpringerLink
Log in

Paracrine-mediated osteoclastogenesis by the osteosarcoma MG63 cell line: is RANKL/RANK signalling really important?

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Although in the past little attention has been paid to the influence of osteosarcoma cells in osteoclast function, recent studies suggest a close relationship between osteosarcoma aggressiveness and osteoclastic activity. The present study addresses the paracrine effects of MG63 cells, a human osteosarcoma-derived cell line, on the differentiation of peripheral blood osteoclast precursor cells (PBMC). PBMC were cultured for 21 days in the presence of conditioned media from MG63 cell cultures (CM) collected at 48 h (CM_MG1), 7 days (CM_MG2) and 14 days (CM_MG3). MG63 cell cultures displayed the expression of ALP and BMP-2 and, also, the osteoclastogenic genes M-CSF and RANKL, although with a low expression of RANKL. PBMC cultures supplemented with CM presented an evident osteoclastogenic behavior, which was dependent on the culture period of the MG63 cells. The inductive effect appeared to be more relevant for the differentiation and activation genes, c-myc and c-src, and lower for genes associated with osteoclast function. In addition, PBMC cultures displayed increased functional parameters, including calcium phosphate resorbing activity. Assessment of the PBMC cultures in the presence of U0126, PDTC, and indomethacin suggested that in addition to MEK and NFkB pathways, other signaling mechanisms, probably not involving RANKL/RANK interaction, might be activated in the presence of conditioned medium from MG63. In conclusion, MG63 cell line appears to induce a significant paracrine-mediated osteoclastogenic response. Understanding the mechanisms underlying the interaction of osteosarcoma cells and osteoclasts may contribute to the development of new potential approaches in the treatment of such bone metabolic diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Hadjidakis DJ, Androulakis II (2006) Bone remodeling. Ann NY Acad Sci 1092:385–396

    Article  PubMed  CAS  Google Scholar 

  2. Raisz LG (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115:3318–3325

    Article  PubMed  CAS  Google Scholar 

  3. Zaidi M (2007) Skeletal remodeling in health and disease. Nat Med 13:791–801

    Article  PubMed  CAS  Google Scholar 

  4. Clezardin P, Teti A (2007) Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastas 24:599–608

    Article  CAS  Google Scholar 

  5. Datta HK, Ng WF, Walker JA et al (2008) The cell biology of bone metabolism. J Clin Pathol 61:577–587

    Article  PubMed  CAS  Google Scholar 

  6. Boyce BF, Xing L (2008) Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473:139–146

    Article  PubMed  CAS  Google Scholar 

  7. Matsuo K, Irie N (2008) Osteoclast–osteoblast communication. Arch Biochem Biophys 473:201–209

    Article  PubMed  CAS  Google Scholar 

  8. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342

    Article  PubMed  CAS  Google Scholar 

  9. Nicholson GC, Malakellis M, Collier FM et al (2000) Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL). Clin Sci (Lond) 99:133–140

    Article  CAS  Google Scholar 

  10. Hu YS, Zhou H, Myers D et al (2004) Isolation of a human homolog of osteoclast inhibitory lectin that inhibits the formation and function of osteoclasts. J Bone Miner Res 19:89–99

    Article  PubMed  CAS  Google Scholar 

  11. Kim N, Kadono Y, Takami M et al (2005) Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 202:589–595

    Article  PubMed  CAS  Google Scholar 

  12. San-Julian M, Diaz-de-Rada P, Noain E et al (2003) Bone metastases from osteosarcoma. Int Orthop 27:117–120

    PubMed  CAS  Google Scholar 

  13. Avnet S, Longhi A, Salerno M et al (2008) Increased osteoclast activity is associated with aggressiveness of osteosarcoma. Int J Oncol 33:1231–1238

    PubMed  CAS  Google Scholar 

  14. Akiyama T, Dass CR, Choong PF (2008) Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther 7:3461–3469

    Article  PubMed  CAS  Google Scholar 

  15. Akiyama T, Choong PF, Dass CR (2010) RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells. Clin Exp Metastas 27:207–215

    Article  CAS  Google Scholar 

  16. Akiyama T, Dass CR, Shinoda Y et al (2010) Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts. J Pharm Pharmacol 62:470–476

    PubMed  CAS  Google Scholar 

  17. Miyamoto N, Higuchi Y, Mori K et al (2002) Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. Int Immunopharmacol 2:25–38

    Article  PubMed  CAS  Google Scholar 

  18. Itoh K, Udagawa N, Matsuzaki K, Takami M, Amano H, Shinki T et al (2000) Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. J Bone Miner Res 15:1766–1775

    Article  PubMed  CAS  Google Scholar 

  19. Kawase T, Okuda K, Burns DM (2005) Immature osteoblastic MG63 cells possess two calcitonin gene-related peptide receptor subtypes that respond differently to [Cys(Acm)(2,7)] calcitonin gene-related peptide and CGRP(8–37). Am J Physiol Cell Physiol 289:C811–C818

    Article  PubMed  CAS  Google Scholar 

  20. Blair HC, Sidonio RF, Friedberg RC et al (2000) Proteinase expression during differentiation of human osteoclasts in vitro. J Cell Biochem 78:627–637

    Article  PubMed  CAS  Google Scholar 

  21. Lossdorfer S, Schwartz Z, Wang L et al (2004) Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity. J Biomed Mater Res 70:361–369

    Article  CAS  Google Scholar 

  22. Granchi D, Cenni E, Savarino L et al (2002) Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells. Biomaterials 23:2359–2365

    Article  PubMed  CAS  Google Scholar 

  23. Taichman RS, Emerson SG (1996) Human osteosarcoma cell lines MG-63 and SaOS-2 produce G-CSF and GM-CSF: identification and partial characterization of cell-associated isoforms. Exp Hematol 24:509–517

    PubMed  CAS  Google Scholar 

  24. Toma CD, Svoboda M, Arrich F et al (2007) Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors. J Pineal Res 43:206–213

    Article  PubMed  CAS  Google Scholar 

  25. Costa-Rodrigues J, Teixeira CA, Sampaio P et al (2010) Characterisation of the osteoclastogenic potential of human osteoblastic and fibroblastic conditioned media. J Cell Biochem 109:205–216

    PubMed  CAS  Google Scholar 

  26. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254

    Article  PubMed  CAS  Google Scholar 

  27. Hotokezaka H, Sakai E, Ohara N et al (2007) Molecular analysis of RANKL-independent cell fusion of osteoclast-like cells induced by TNF-α, lipopolysaccharide, or peptidoglycan. J Cell Biochem 101:122–134

    Article  PubMed  CAS  Google Scholar 

  28. Yamashita M, Otsuka F, Mukai T et al (2010) Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling. Regul Pept 162:99–108

    Article  PubMed  CAS  Google Scholar 

  29. Hotokezaka H, Sakai E, Kanaoka K et al (2002) U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 277:47366–47372

    Article  PubMed  CAS  Google Scholar 

  30. Yang CR, Wang JH, Hsieh SL et al (2004) Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. Cell Death Differ 11:S97–S107

    Article  PubMed  CAS  Google Scholar 

  31. Yang Q, McHugh KP, Patntirapong S et al (2008) VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin. Matrix Biol 27:589–599

    Article  PubMed  Google Scholar 

  32. Kim HJ, Lee Y, Chang EJ et al (2007) Suppression of osteoclastogenesis by N,N-dimethyl-d-erythro-sphingosine: a sphingosine kinase inhibition-independent action. Mol Pharmacol 72:418–428

    Article  PubMed  CAS  Google Scholar 

  33. Hall TJ, Schaeublin M, Jeker H et al (1995) The role of reactive oxygen intermediates in osteoclastic bone resorption. Biochem Biophys Res Commun 207:280–287

    Article  PubMed  CAS  Google Scholar 

  34. Kellinsalmi M, Parikka V, Risteli J et al (2007) Inhibition of cyclooxygenase-2 down-regulates osteoclast and osteoblast differentiation and favours adipocyte formation in vitro. Eur J Pharmacol 572:102–110

    Article  PubMed  CAS  Google Scholar 

  35. Kawashima M, Fujikawa Y, Itonaga I et al (2009) The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro. Mod Rheumatol 19:192–198

    Article  PubMed  CAS  Google Scholar 

  36. Hessle L, Johnson KA, Anderson HC et al (2002) Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci USA 99:9445–9449

    Article  PubMed  CAS  Google Scholar 

  37. Torii Y, Hitomi K, Yamagishi Y et al (1996) Demonstration of alkaline phosphatase participation in the mineralization of osteoblasts by antisense RNA approach. Cell Biol Int 20:459–464

    Article  PubMed  CAS  Google Scholar 

  38. Chen D, Zhao M, Mundy GR (2004) Bone morphogenetic proteins. Growth Factors 22:233–241

    Article  PubMed  CAS  Google Scholar 

  39. Pixley FJ, Stanley ER (2004) CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol 14:628–638

    Article  PubMed  CAS  Google Scholar 

  40. Knowles HJ, Athanasou NA (2008) Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J Pathol 215:56–66

    Article  PubMed  CAS  Google Scholar 

  41. Yasuda H, Shima N, Nakagawa N et al (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–3602

    Article  PubMed  CAS  Google Scholar 

  42. Zhao Q, Shao J, Chen W et al (2007) Osteoclast differentiation and gene regulation. Front Biosci 12:2519–2529

    Article  PubMed  CAS  Google Scholar 

  43. de Vries TJ, Mullender MG, van Duin MA et al (2009) The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol Cancer Res 7:476–488

    Article  PubMed  Google Scholar 

  44. Battaglino R, Kim D, Fu J et al (2002) c-myc is required for osteoclast differentiation. J Bone Miner Res 17:763–773

    Article  PubMed  CAS  Google Scholar 

  45. Logar DB, Komadina R, Preželj J et al (2007) Expression of bone resorption genes in osteoarthritis and in osteoporosis. J Bone Miner Metab 25:219–225

    Article  PubMed  CAS  Google Scholar 

  46. Bradley EW, Ruan MM, Vrable A et al (2008) Pathway crosstalk between Ras/Raf and PI3K in promotion of M-CSF-induced MEK/ERK-mediated osteoclast survival. J Cell Biochem 104:1439–1451

    Article  PubMed  CAS  Google Scholar 

  47. Roodman GD (1999) Cell biology of the osteoclast. Exp Hematol 27:1229–1241

    Article  PubMed  CAS  Google Scholar 

  48. Strait K, Li Y, Dillehay DL et al (2008) Suppression of NF-kappaB activation blocks osteoclastic bone resorption during estrogen deficiency. Int J Mol Med 21:521–525

    PubMed  CAS  Google Scholar 

  49. Okada Y, Pilbeam C, Raisz L et al (2003) Role of cyclooxygenase-2 in bone resorption. J UOEH 25:185–195

    PubMed  CAS  Google Scholar 

  50. Blackwell KA, Raisz LG, Pilbeam CC (2010) Prostaglandins in bone: bad cop, good cop? Trends Endocrinol Metab 21:294–301

    Article  PubMed  CAS  Google Scholar 

  51. Cenni E, Granchi D, Ciapetti G et al (2001) Interleukin-6 expression by osteoblast-like MG63 cells challenged with four acrylic bone cements. J Biomater Sci 12:243–253

    Article  CAS  Google Scholar 

  52. Kakonen SM, Mundy GR (2003) Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97:834–839

    Article  PubMed  Google Scholar 

  53. Morrissey C, Vessella RL (2007) The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem 101:873–886

    Article  PubMed  CAS  Google Scholar 

  54. Michael H, Harkonen PL, Kangas L et al (2007) Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Br J Pharmacol 151:384–395

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant from Faculty of Dental Medicine, University of Porto, Portugal.

Author information

Authors and Affiliations

  1. Laboratório de Farmacologia e Biocompatibilidade Celular, Faculdade de Medicina Dentária, Universidade do Porto, Rua Dr. Manuel Pereira da Silva, 4200-393, Porto, Portugal

    J. Costa-Rodrigues, C. A. Teixeira & M. H. Fernandes

  2. Faculdade de Ciências, Universidade do Porto, Porto, Portugal

    C. A. Teixeira

Authors
  1. J. Costa-Rodrigues
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. A. Teixeira
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. H. Fernandes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. H. Fernandes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Costa-Rodrigues, J., Teixeira, C.A. & Fernandes, M.H. Paracrine-mediated osteoclastogenesis by the osteosarcoma MG63 cell line: is RANKL/RANK signalling really important?. Clin Exp Metastasis 28, 505–514 (2011). https://doi.org/10.1007/s10585-011-9387-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-011-9387-7

Keywords

Search

Navigation